Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
Gavin Hui(University of California, Los Angeles), Alexandra Drakaki(Columbia University Irving Medical Center), Christopher Hannigan(University of California, Los Angeles), Dayna J Isaacs, Allan J. Pantuck(University of California System), Dimitrios Stefanoudakis(APLA Health), Yuliya Zektser(University of California, Los Angeles)
Cited by 6
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
|Current Issues in Molecular Biology|2024|78